Ozempic and its cousins have become the most argued-about drugs in modern medicine, and podcasts are where the real argument is happening. Doctors, scientists, and founders keep circling back to the same questions: does the muscle loss matter, does the weight come back, and are these actually longevity drugs in disguise. We combed our full library of episode summaries and pulled the ten conversations that treat GLP-1 drugs with the most nuance, not hype.
Expect a metabolic scientist who thinks insulin (not the injection) is the real story, a Stanford geneticist who put himself on Mounjaro and watched his own labs change, a founder whose company beats GLP-1 adherence rates without a needle, and a tech investor micro-dosing tirzepatide for reasons that have nothing to do with weight loss. Whatever side of the debate you're on, these episodes will sharpen it.
Insulin Expert: How To 'Drain' Your Liver of Fat (Do This!)
Bikman is a metabolic scientist who spends most of this episode building the case for insulin, not calories, as the master hormone behind fat storage, but he doesn't dodge GLP-1 drugs when the topic comes up. He cites the sobering numbers directly: roughly 70% of people quit GLP-1 drugs within two years, often from constant nausea, and about 40% of the weight lost is fat-free mass, muscle and bone that may never come back. He pairs that with hands-on data from his own ketone protocol, live-testing exogenous ketones on the host's bloodwork mid-conversation. Listen if you want the physiological argument against GLP-1s as a standalone fix, from someone who has the fat-cell research to back it up.
Read the full episode notesTransform Your Metabolic Health & Longevity by Knowing Your Unique Biology | Dr. Michael Snyder
Snyder is a Stanford geneticist who discovered he was type 2 diabetic despite being thin and fit, and this episode is essentially his own GLP-1 case study. He reveals his A1C dropped from 8.4 to 5.7 and his fat 'evaporated' on whole-body MRI while on the drugs, but he backed off Mounjaro because he looked gaunt, a firsthand account of the tradeoff most guests only discuss in the abstract. He also flags that GLP-1 drugs are being investigated as potential longevity and cognition-enhancing drugs, well beyond diabetes and weight loss. This is the episode for anyone who wants the personal-data version of the GLP-1 conversation, backed by a genetics lab.
Read the full episode notesTools for Nutrition & Fitness | Dr. Layne Norton
Norton opens by laying out a hierarchy of scientific evidence, then applies it directly to GLP-1 drugs, arguing they're a major net positive for public health and comparing dismissing them to refusing a drug that cured opioid addiction. It's a notably blunt take from someone whose entire reputation is built on evidence-based nutrition rather than trend-chasing. He works through the same evidence-first lens on protein, seed oils, sweeteners, and fasting, so you get the GLP-1 verdict inside a broader lesson on how to actually weigh a claim. Good for anyone tired of hot takes and looking for someone who shows their work.
Read the full episode notesReversing Type 2 Diabetes and Rowing 2,750 Miles — Sami Inkinen of Virta Health
Inkinen founded Virta Health after his own bloodwork came back pre-diabetic despite training 15 hours a week as a triathlete, and he built a nutrition-and-monitoring model that reverses type 2 diabetes without drugs. The standout reveal here: Virta patients hit 83% adherence at one year, roughly twice the 30-50% adherence typically seen with GLP-1 drugs, driven mainly by how good patients feel rather than willpower. He also shares a randomized trial showing Virta's nutrition therapy added to chemotherapy produced about 35% life extension in stage-4 pancreatic cancer patients. Worth a listen for anyone weighing GLP-1 drugs against a non-pharmaceutical alternative with real trial data behind it.
Read the full episode notesTim Ferriss with Kevin Rose — Live 10th Anniversary Random Show!
Buried inside this wide-ranging live anniversary episode is a sharp, specific GLP-1 fact: GLP-1 inhibitors show a 20% reduction in cardiovascular events even after controlling for weight loss, a benefit that goes beyond the scale. Ferriss and Rose also get into why muscle loss on these drugs often traces back to insufficient protein and calorie intake, sometimes requiring testosterone replacement to counter it. The rest of the episode covers Bitcoin retirement accounts, accelerated TMS for OCD and depression, and Ferriss hitting 1 billion podcast downloads, so it's a grab-bag, but the GLP-1 segment holds its own. Good for listeners who want the cardiovascular angle explained plainly.
Read the full episode notesThe Random Show — Sobriety, Fasting, Home Defense, Vibe Coding, Roblox, and More
Rose reveals he's been micro-dosing the GLP-1 drug Zepbound (tirzepatide) at well under one unit via insulin syringe, not for weight loss but to trim about 30% off his glucose spikes and repair insulin sensitivity, an unusual off-label use most GLP-1 coverage never mentions. He frames it alongside Ferriss's own ketosis-then-fasting protocol and both men's concern about Alzheimer's prevention, with guidance credited to researcher Rhonda Patrick. The episode's real hook is Rose's 100 days of sobriety after a liver scare, but the micro-dosing detail is the sharpest GLP-1 angle in our whole library. Best for readers curious about low-dose, non-weight-loss uses of these drugs.
Read the full episode notesHow to Overcome Addiction to Substances or Behaviors | Dr. Keith Humphreys
Humphreys is a Stanford addiction expert who reveals he's working with the VA and Novo Nordisk to study GLP-1 drugs like semaglutide as a treatment for alcohol use disorder, a use case almost nobody associates with these medications. It's one detail inside a much broader tour of addiction science, covering how industries engineer addiction for profit and why Alcoholics Anonymous outperforms gold-standard therapies in a Cochrane review. The GLP-1 segment lands because it reframes the drugs as neurological tools, not just metabolic ones. Recommended for anyone tracking where GLP-1 research is headed next, beyond weight and diabetes.
Read the full episode notesAnti-Aging Expert: Stop Touching Receipts Immediately! The Fast Way To Shrink Visceral Fat!
Patrick's episode is mostly about visceral fat, endocrine-disrupting plastics, and her own supplement stack, but she gives a clear-eyed, balanced look at GLP-1 weight-loss drugs that doesn't oversell or dismiss them. Her key point: most people regain weight after stopping GLP-1 drugs as hunger returns 'with a vengeance,' a finding that reframes these drugs as a maintenance commitment rather than a cure. She pairs that with hard numbers on visceral fat, like its doubling of early-mortality risk, giving the GLP-1 discussion real metabolic context. Good for listeners who want the rebound-weight risk explained without an agenda.
Read the full episode notesThe Anti-Obesity Doctor: If You Don't Exercise, This Is What's Happening To You! - Gabrielle Lyon
Lyon, a muscle-centric medicine physician, pushes back hard on the popular narrative that Ozempic itself causes muscle loss, stating flatly that the drug does not cause it and that muscle loss on GLP-1s comes from failing to train and eat enough protein. She also calls out what she sees as a double standard: prescribing drugs for obesity is broadly accepted while prescribing testosterone for muscle preservation gets stigmatized. The rest of the conversation builds her case that skeletal muscle, not obesity, is the real lever for longevity and brain health. Worth hearing if you're on a GLP-1 drug and want the muscle-preservation counterargument.
Read the full episode notesHow to Navigate Menopause & Perimenopause for Maximum Health & Vitality | Dr. Mary Claire Haver
Haver's episode is primarily a deep dive into perimenopause and menopause, debunking the fear around hormone replacement therapy that followed a misread 2002 study, but GLP-1 drugs come up directly in her audience Q&A alongside libido, sleep, and mental health during the menopause transition. It's a useful angle because so much GLP-1 coverage skips the specific hormonal context of midlife women, where visceral fat can jump from roughly 8% to 23% of body fat through the transition with no diet change. Pair this one with the Bikman or Snyder episodes above for the fuller GLP-1 picture as it applies specifically to women in perimenopause. Recommended for women navigating weight, hormones, and these drugs at the same time.
Read the full episode notesThat's ten of the sharpest GLP-1 conversations in our library, from the muscle-loss debate to off-label micro-dosing to what happens when you stop. Browse the full episode summaries on Episode Notes for more of what these podcasts actually said, minus the filler.